Clinical trials investigating tagraxofusp in BPDCN and beyond

Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical trials that are investigating tagraxofusp. Currently, tagraxofusp is approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients older than two years old. There are a number of ongoing Phase II clinical trials in myelofibrosis and chronic myeloid leukemia (CML), including trials in combination with venetoclax or chemotherapy. There are also trials investigating triplet combinations with venetoclax and azacitidine in acute myeloid leukemia (AML). The use of tagraxofusp in post-transplant patients has not been studied yet, but there are clinical trials enrolling. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).